APP and Alzheimer disease: To test this hypothesis, we applied HFD treatment to an AppNL−F/NL−F knock‐in mouse model of AD, which carries a humanized β‐amyloid (Aβ) sequence with two pathogenic mutations: Swedish “NL” and Iberian “F” at the authentic mouse App locus, thereby increasing the production of the pathogenic Aβ without the overproduction of APP.